Important Note: Redirection of Services to ChiCTR
We would like to inform you that the Clinical Trial Registry page will discontinue the function of updating trial information directly on this platform. However, you will still be able to view the existing registration details. For any updates to trial information, you can use the China Clinical Trial Registry (ChiCTR) directly at https://www.chictr.org.cn. This change will be fully implemented by 2024-Aug-05. Thank you for your attention.
CUHK_CCT00147
2007-12-18
Prospective
N/A
Departmental
Department of Paediatrics, The Chinese University of Hong Kong
N/A
Albert Martin LI
Department of Paediatrics, PWH, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020; email: albertm68mcli@yahoo.com
Albert Martin LI
Department of Paediatrics, PWH, Shatin, Hong Kong
Telephone #: 26322859; Fax #: 26360020; email: albertm68mcli@yahoo.com
A randomized controlled study of the effectiveness of azithromycin in preventing post-respiratory syncytial virus bronchiolitis wheezing
N/A
Yes
2007-12-11
Post-respiratory syncytial virus bronchiolitis wheezing
Drug
Azithromycin
3 days
Placebo
Inclusion criteria: 1. previously well infants less than or equal to 12 months of age; 2. first episode of wheezing requiring hospitalization, and with a clinical diagnosis of bronchiolitis. Bronchiolitis is diagnosed based on clinical findings including wheezing or wheezing with crackles preceded by upper respiratory tract infection symptoms, and respiratory distress with retractions; 3. admitted in hospital for <24 hours; 4. laboratory confirmed presence of RSV in nasopharyngeal aspirate, and 5. signed written informed consent. Exclusion criteria: 1. infants with any cardio-respiratory illness, immunodeficiency or were born prematurely (gestational age <37 weeks); 2. infants who had received corticosteroids within 24 hours before presentation; 3. infants who had received antibiotic treatment less than seven days before hospital admission, and 4. infants requiring mechanical ventilation.
Randomized
Placebo
Double-blind
Parallel
2008-02-15
70
Not Yet Recruiting
The primary outcome is the number of wheezing attacks in the following 12 months after the initial illness.
Secondary outcomes include length of hospital stay (LOS) (in hours) defined as the time between study entry and the actual time that the subject is declared fit for discharge.
2013-06-22
Yes
N/A
|
|
|
|
|
---|---|---|---|---|
No documents yet. |